7Yagihashi S. Recent advances ij clinical practice and in Basicresearch on diabetic neuropathy[J].Brain Nerve,2011,63(6):571.
8Hamada Y, Nakamura J, Naruse K,et al. Epalrestat an aldose reductase inhibitor, reduces the levels of Nepsilan-(carboxymethyl) Lysine protein adducts and their precursors in erythrocytes form diabetic patients[J]. Diabetes Care,2000,23(lO): 1539-1544.
9Hotta N, Kawamori R, Fukuda M,et al.Short Report:Treatment long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvaseular complications:multivari-ate epidemiological analysis on patient background factors and severity of diabetic neuropathy[J].Diabet Med,2012,29(12):1529-1533.
10Hou Q, Lin Z, Mayo MS, et al. Is symptom relief associated with reduc- tion in gastric retention after gastric electrical stimulation treatment in patients with gastroparesis? A sensitivity analysis with logistic regres- sion models [ J ]. Neurogastroenterol Moti1,2012,24 (7) :639 - 645.
